Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis

(2014) Tinghong Ye et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

(2013) F. Andre et al.   CLINICAL CANCER RESEARCH

Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer

(2013) T. C. Harding et al.   Science Translational Medicine

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

(2012) P. R. Gavine et al.   CANCER RESEARCH

A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane

(2012) Yasuhiro Suzuki et al.   International Journal of Clinical Oncology

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

(2012) E. Bello et al.   MOLECULAR CANCER THERAPEUTICS

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

(2012) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS

A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance

(2012) Masakazu Toi et al.   Breast Cancer

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

(2011) Koichi Azuma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer

(2011) Juan P. Cerliani et al.   BREAST CANCER RESEARCH AND TREATMENT

Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies

(2011) Sihua Peng et al.   BREAST CANCER RESEARCH AND TREATMENT

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

(2011) Ezia Bello et al.   CANCER RESEARCH

FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo

(2011) Rachel Sharpe et al.   CLINICAL CANCER RESEARCH

Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor

(2011) Elisa Frullanti et al.   EUROPEAN JOURNAL OF CANCER PREVENTION

High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1

(2011) Elin Karlsson et al.   GENES CHROMOSOMES & CANCER

Mechanisms of FGFR3 actions in endocrine resistant breast cancer

(2011) D.C. Tomlinson et al.   INTERNATIONAL JOURNAL OF CANCER

Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease

(2011) N. Itoh et al.   JOURNAL OF BIOCHEMISTRY

Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer

(2011) Shanshan Sun et al.   JOURNAL OF SURGICAL ONCOLOGY

Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis

(2010) J. H. Dey et al.   CANCER RESEARCH

A Single Nucleotide Change in the Mouse Genome Accelerates Breast Cancer Progression

(2010) N. Seitzer et al.   CANCER RESEARCH

Fibroblast Growth Factor Receptor 4 Regulates Tumor Invasion by Coupling Fibroblast Growth Factor Signaling to Extracellular Matrix Degradation

(2010) N. Sugiyama et al.   CANCER RESEARCH

GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

(2010) A. Bai et al.   CANCER RESEARCH

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

(2010) Tianjun Zhou et al.   Chemical Biology & Drug Design

Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors

(2010) Roshani R. Patel et al.   EUROPEAN JOURNAL OF CANCER

Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics

(2010) Masaru Katoh   Expert Review of Anticancer Therapy

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

(2010) Wei-Sheng Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes

(2010) Cathy B Moelans et al.   MODERN PATHOLOGY

Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

(2010) E. M. Haugsten et al.   MOLECULAR CANCER RESEARCH

The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases

(2010) R. S. Bhide et al.   MOLECULAR CANCER THERAPEUTICS

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

(2010) N Turner et al.   ONCOGENE

Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate

(2009) Christine Y. Shiang et al.   BREAST CANCER RESEARCH AND TREATMENT

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Identification of Novel Gene Amplifications in Breast Cancer and Coexistence of Gene Amplification with an Activating Mutation of PIK3CA

(2009) M. Kadota et al.   CANCER RESEARCH

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

(2009) F. Andre et al.   CLINICAL CANCER RESEARCH

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

(2009) A Roidl et al.   ONCOGENE

Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer

(2008) I. Bernard-Pierrot et al.   CANCER RESEARCH

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women

(2008) J. Liang et al.   CARCINOGENESIS

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer

(2008) D. Meijer et al.   ENDOCRINE-RELATED CANCER

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer

(2008) Simon N Stacey et al.   NATURE GENETICS

Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer

(2008) Kerstin B Meyer et al.   PLOS BIOLOGY

Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics

(2008) Montserrat Garcia-Closas et al.   PLoS Genetics